Integrum AB Series B (INTEG-B) - Total Assets
Based on the latest financial reports, Integrum AB Series B (INTEG-B) holds total assets worth Skr203.60 Million SEK (≈ $21.91 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Integrum AB Series B (INTEG-B) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Integrum AB Series B - Total Assets Trend (2013–2025)
This chart illustrates how Integrum AB Series B's total assets have evolved over time, based on quarterly financial data. See Integrum AB Series B (INTEG-B) shareholders funds for net asset value and shareholders' equity analysis.
Integrum AB Series B - Asset Composition Analysis
Current Asset Composition (December 2025)
Integrum AB Series B's total assets of Skr203.60 Million consist of 41.1% current assets and 58.9% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 9.4% |
| Accounts Receivable | Skr35.18 Million | 17.3% |
| Inventory | Skr29.44 Million | 14.5% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr66.62 Million | 32.7% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Integrum AB Series B's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see INTEG-B company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Integrum AB Series B's current assets represent 41.1% of total assets in 2025, a decrease from 71.7% in 2013.
- Cash Position: Cash and equivalents constituted 9.4% of total assets in 2025, down from 27.9% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 32.0% of total assets, an increase from 2.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 32.7% of total assets.
Integrum AB Series B Competitors by Total Assets
Key competitors of Integrum AB Series B based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
COCHLEAR LTD ADR 1/2/O.N.
F:OC50
|
Germany | €2.83 Billion |
|
Novocure Ltd
NASDAQ:NVCR
|
USA | $787.93 Million |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Bactiguard Holding AB (publ)
ST:BACTI-B
|
Sweden | Skr537.34 Million |
|
Sequana Medical NV
BR:SEQUA
|
Belgium | €14.57 Million |
Integrum AB Series B - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.77 | 4.54 | 13.54 |
| Quick Ratio | 1.80 | 3.31 | 12.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr53.49 Million | Skr78.69 Million | Skr135.62 Million |
Integrum AB Series B - Advanced Valuation Insights
This section examines the relationship between Integrum AB Series B's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.29 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | 0.2% |
| Total Assets | Skr203.60 Million |
| Market Capitalization | $23.78 Million USD |
Valuation Analysis
Below Book Valuation: The market values Integrum AB Series B's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Integrum AB Series B's assets grew by 0.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Integrum AB Series B (2013–2025)
The table below shows the annual total assets of Integrum AB Series B from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr203.60 Million ≈ $21.91 Million |
+0.17% |
| 2024-12-31 | Skr203.25 Million ≈ $21.87 Million |
+23.29% |
| 2023-12-31 | Skr164.86 Million ≈ $17.74 Million |
-0.19% |
| 2022-12-31 | Skr165.17 Million ≈ $17.77 Million |
-8.46% |
| 2021-12-31 | Skr180.44 Million ≈ $19.42 Million |
+384.93% |
| 2020-12-31 | Skr37.21 Million ≈ $4.00 Million |
+15.57% |
| 2019-12-31 | Skr32.20 Million ≈ $3.46 Million |
+29.28% |
| 2018-12-31 | Skr24.90 Million ≈ $2.68 Million |
-5.60% |
| 2017-12-31 | Skr26.38 Million ≈ $2.84 Million |
+33.42% |
| 2016-12-31 | Skr19.77 Million ≈ $2.13 Million |
+94.44% |
| 2015-12-31 | Skr10.17 Million ≈ $1.09 Million |
+58.49% |
| 2014-12-31 | Skr6.42 Million ≈ $690.46K |
-25.77% |
| 2013-12-31 | Skr8.64 Million ≈ $930.13K |
-- |
About Integrum AB Series B
Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company provides prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system offers protection to the patient by avoidi… Read more